Clinical Trial Results:
A Phase II, Randomized, Double-blind, Placebo-controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients with Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Summary
|
|
EudraCT number |
2014-000275-14 |
Trial protocol |
SE IE GB |
Global end of trial date |
13 Oct 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Oct 2017
|
First version publication date |
21 Oct 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GB29260
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02099656 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
F. Hoffmann-La Roche AG
|
||
Sponsor organisation address |
Grenzacherstrasse 124, Basel, Switzerland, CH-4070
|
||
Public contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
|
||
Scientific contact |
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Oct 2016
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Oct 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the trial is to evaluate the effect of lebrikizumab in reducing airway eosinophilic inflammation in subjects with uncontrolled asthma, who are using inhaled corticosteroid (ICS) treatment and a second controller medication, as measured by a relative change in the number of airway submucosal eosinophils per surface area of basal lamina (cells per square millimetre [cells/mm^2]) obtained via endobronchial biopsy at Week 12 compared to baseline.
|
||
Protection of trial subjects |
All study subjects were required to read and sign an Informed Consent Form.
|
||
Background therapy |
Subjects continued their ICS controller therapy, as they were receiving prior to screening, throughout the study. ICS therapy included 500–2000 micrograms per day (mcg/day) of fluticasone propionate dry powder inhaler (DPI) or equivalent. Subjects also continued their second asthma controller therapy, as they were receiving prior to screening, throughout the study. The following second controller medications were included in the study: long-acting beta-agonist (LABA), leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Nov 2014
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
2 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Canada: 13
|
||
Country: Number of subjects enrolled |
United States: 34
|
||
Country: Number of subjects enrolled |
France: 4
|
||
Country: Number of subjects enrolled |
United Kingdom: 6
|
||
Country: Number of subjects enrolled |
Sweden: 7
|
||
Worldwide total number of subjects |
64
|
||
EEA total number of subjects |
17
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
63
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Subjects 18-75 years of age (inclusive) with uncontrolled asthma on inhaled corticosteroid (ICS) therapy and on an eligible second controller medication were recruited. The screening period was three weeks and included four visits (Visits 1, 2, 3, and 4a) and a final assessment of eligibility prior to randomisation at Visit 4b. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Asthma had to be diagnosed >/= 12 months before first screening visit. Bronchodilator response, which was defined as >/= 12% relative improvement in forced expiratory volume in 1 second (FEV1) after bronchodilator administration, had to be demonstrated within the 12 months before Visit 1 or at Visit 1, 2, or 3 of screening. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall Period
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Carer, Investigator | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Subjects with uncontrolled asthma on ICS therapy and a second controller medication received subcutaneous (SC) injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
Matching placebo was administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
|
|||||||||||||||
Arm title
|
Lebrikizumab | |||||||||||||||
Arm description |
Subjects with uncontrolled asthma on inhaled corticosteroids (ICS) therapy and a second controller medication received SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Lebrikizumab
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
RO5490255
|
|||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled pen
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
Lebrikizumab 125 milligrams (mg) was administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with uncontrolled asthma on ICS therapy and a second controller medication received subcutaneous (SC) injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lebrikizumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with uncontrolled asthma on inhaled corticosteroids (ICS) therapy and a second controller medication received SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects with uncontrolled asthma on ICS therapy and a second controller medication received subcutaneous (SC) injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. | ||
Reporting group title |
Lebrikizumab
|
||
Reporting group description |
Subjects with uncontrolled asthma on inhaled corticosteroids (ICS) therapy and a second controller medication received SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. |
|
|||||||||||||||||||
End point title |
Relative Change From Baseline in the Number of Airway Submucosal Eosinophils per Surface Area of Basal Lamina | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab in reducing airway eosinophilic inflammation the relative change from baseline in the number of airway submucosal eosinophils per surface area of basal lamina (cells per square millimetre [cells/mm^2]) was measured after an endobronchial biopsy was performed. Baseline results are presented as 10^9 cells per square metre (10^9 cells/m^2). Relative change was defined as the absolute change from baseline to Week 12, divided by the value at baseline and presented as percentage. The Primary analysis Patients (PP) population was defined as a subset of subjects from the intent-to-treat (ITT) population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Placebo versus Lebrikizumab | ||||||||||||||||||
Comparison groups |
Placebo v Lebrikizumab
|
||||||||||||||||||
Number of subjects included in analysis |
51
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Mean difference (net) | ||||||||||||||||||
Point estimate |
7.3
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-82.5 | ||||||||||||||||||
upper limit |
97.6 |
|
|||||||||||||||||||
End point title |
Absolute Change From Baseline in Number of Airway Submucosal Eosinophils per Surface Area of Basal Lamina | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the absolute change in the number of airway submucosal eosinophils per surface area of basal lamina (cells/mm^2) was measured after an endobronchial biopsy was performed. Results are presented as 10^9 cells/m^2. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Relative Change From Baseline in the Number of Airway Epithelial Eosinophils per Surface Area of Basal Lamina | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the relative change in the number of airway epithelial eosinophils per surface area of basal lamina (cells/mm^2) was measured after an endobronchial biopsy was performed. Baseline results are presented as 10^9 cells/m^2. Relative change was defined as the absolute change from baseline to Week 12, divided by the value at baseline and presented as percentage. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Absolute Change From Baseline in Number of Airway Epithelial Eosinophils per Surface Area of Basal Lamina | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the absolute change in the number of airway epithelial eosinophils per surface area of basal lamina (cells/mm^2) was measured after an endobronchial biopsy was performed. Results are presented as 10^9 cells/m^2. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Relative Change From Baseline in Number of Airway Submucosal Eosinophils per Volume of Submucosa | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the relative change in the number of airway submucosal eosinophils per volume of submucosa (cells per cubic millimetre [cells/mm^3]) was measured after an endobronchial biopsy was performed. Baseline results are presented as 10^9 cells/litre (L). Relative change was defined as the absolute change from baseline to Week 12, divided by the value at baseline and presented as percentage. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Absolute Change From Baseline in Number of Airway Submucosal Eosinophils per Volume of Submucosa | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the absolute change in the number of airway submucosal eosinophils per volume of submucosa (cells/mm^3) was measured after an endobronchial biopsy was performed. Results are presented as 10^9 cells/L. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Relative Change From Baseline in Number of Airway Epithelial Eosinophils per Volume of Epithelium | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the relative change in the number of airway epithelial eosinophils per volume of epithelium (cells/mm^3) was measured after an endobronchial biopsy was performed. Baseline results are presented as 10^9 cells/L. Relative change was defined as the absolute change from baseline to Week 12, divided by the value at baseline and presented as percentage. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Absolute Change From Baseline in Number of Airway Epithelial Eosinophils per Volume of Epithelium | ||||||||||||||||||
End point description |
To evaluate the effect of lebrikizumab on airway eosinophilic inflammation the absolute change in the number of airway epithelial eosinophils per volume of epithelium (cells/mm^3) was measured after an endobronchial biopsy was performed. Results are presented as 10^9 cells/L. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Blood Eosinophil Count | |||||||||||||||||||||||||||||||||
End point description |
Blood eosinophil counts were performed at multiple time points from baseline (BL) to Week 20. The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
|||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, Week 20
|
|||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Change From Baseline in Immunoglobulin E (IgE) Levels | ||||||||||||||||||||||||
End point description |
IgE levels were measured at multiple time points from baseline (BL) to Week 20.The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point. Results are presented in International Units per millilitre (IU/mL).
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 12, Week 20
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Change From Baseline in Serum Periostin Levels | ||||||||||||||||||||||||
End point description |
Serum periostin levels were measured at multiple time points from baseline (BL) to Week 20.The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point. Results are presented in nanograms per millilitre (ng/mL).
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 12, Week 20
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Chemokine Ligand (CCL)-17 Levels | ||||||||||||
End point description |
CCL-17 levels were planned to be measured at multiple time points from baseline (BL) to Week 20.The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 1, Week 12, Week 20
|
||||||||||||
|
|||||||||||||
Notes [1] - CCL-17 data were not available for analysis. [2] - CCL-17 data were not available for analysis. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Lung Epithelial Cell Chloride Channel Accessory 1 (CLCA1) Gene Expression | ||||||||||||||||||
End point description |
CLCA1 gene expression at the messenger ribonucleic acid (mRNA) transcript levels in lung epithelial cells was measured by RNA-sequencing at baseline (BL) and Week 12. Change in gene expression levels is reported as reads per kilobase million (RPKM) at Week 12 relative to BL.The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From Baseline to Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Lung Epithelial Cell SerpinB2 Gene Expression | ||||||||||||||||||
End point description |
SerpinB2 gene expression at the mRNA transcript levels in lung epithelial cells was measured by RNA-sequencing at baseline (BL) and Week 12. Change in gene expression levels is reported as RPKM at Week 12 relative to BL.The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Lung Epithelial Cell CCL-26 Gene Expression | ||||||||||||||||||
End point description |
CCL-26 gene expression at the mRNA transcript levels in lung epithelial cells was measured by RNA-sequencing at baseline (BL) and Week 12. Change in gene expression levels is reported as RPKM at Week 12 relative to BL. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Lung Epithelial Cell Nitric Oxide Synthase 2 (NOS2) Gene Expression | ||||||||||||||||||
End point description |
NOS2 gene expression at the mRNA transcript levels in lung epithelial cells was measured by RNA-sequencing at baseline (BL) and Week 12. Change in gene expression levels is reported as RPKM at Week 12 relative to BL. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Lung Epithelial Cell Periostin (POSTN) Gene Expression | ||||||||||||||||||
End point description |
POSTN gene expression at the mRNA transcript levels in lung epithelial cells was measured by RNA-sequencing at baseline (BL) and Week 12. Change in gene expression levels is reported as RPKM at Week 12 relative to BL. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline, Week 12
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Relative Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) | |||||||||||||||||||||||||||
End point description |
Description: FeNO was measured at multiple time points from baseline (BL) to Week 12. At BL FeNO is reported as parts per billion (ppb). Relative change was defined as the absolute change from baseline to each time point, divided by the value at baseline and presented as percentage. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 4, Week 8, Week 12
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Relative Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | |||||||||||||||||||||||||||
End point description |
FEV1 was measured at multiple time points from baseline (BL) to Week 12. At BL FEV1 is reported as volume in litres (L). Relative change was defined as the absolute change from baseline to each time point, divided by the value at baseline and presented as percentage. The PP population was defined as a subset of subjects from the ITT population who received at least one dose of the study drug, and who had evaluable biopsies available for both baseline (Visit 4a) and Week 12 visits. Subjects were grouped according to actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 4, Week 8, Week 12
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Treatment-Emergent Adverse Events | ||||||||||||
End point description |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Baseline to Week 20
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects With Anti-Therapeutic Antibodies (ATAs) to Lebrikizumab | ||||||||||||||||||
End point description |
Presence of ATAs to lebrikizumab was measured at baseline and up to Week 20. Reported is the percentage of subjects with ATAs to lebrikizumab at baseline and post-baseline. The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From Baseline up to Week 20
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Serum Lebrikizumab Concentration at Week 12 [3] | ||||||||
End point description |
To measure serum lebrikizumab concentration blood samples were taken from subjects in the lebrikizumab arm before dosing at Week 12. The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Pre-dose (Hour 0) at Week 12
|
||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Serum lebrikizumab concentration was only measured in the arm that received lebrikizumab treatment. Therefore, data are only reported for the lebrikizumab arm. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Change From Baseline in CCL-13 Levels | ||||||||||||||||||||||||
End point description |
CCL-13 levels were measured at multiple time points from baseline (BL) to Week 20. The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received. The number of subjects analysed is indicated by n for each arm at each time point. Results are presented in picograms per millilitre (pg/mL).
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, Week 1, Week 12, Week 20
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From baseline to Week 20
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The safety evaluable population was defined as all subjects who received at least one dose of study drug, with subjects grouped according to the actual treatment received.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lebrikizumab
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with uncontrolled asthma on inhaled corticosteroids (ICS) therapy and a second controller medication received SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects with uncontrolled asthma on ICS therapy and a second controller medication received subcutaneous (SC) injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Jun 2014 |
Required abstinence or highly effective contraception starting on Visit 1 (Day − 21). Removed a duplicate exclusion criterion. Updated Medical Monitor contact information. Clarified who within the Sponsor will be unblinded to eosinophil counts. |
||
29 Sep 2015 |
Updated the screening period inhaled corticosteroid (ICS)-compliance requirement from 80% to 70%. Updated the time to re-screening after a subject was deemed non-compliant with ICS during screening from 4 to 6 weeks to at least 1 week. Clarified that the criteria for demonstrating uncontrolled asthma is an Asthma Control Questionnaire-5 score of >/= 1.5 and the presence of asthma symptoms. Corrected an error in the previous Protocol for Appendix 1 visit assessment time
windows. Updated Internal Monitoring Committee membership and functioning. Updated the total planned enrollment from 120 to 80 subjects. Updated the analysis plan to include an optional unblinded interim analysis of efficacy and safety. Updated Medical Monitor contact information. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |